This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.
Background
This week, we will maybe not expect the worse, while discussing the COMPASS post hoc analysis. Are PPIs so bad for the kidneys?
Background
This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.
Background
This week, we will discuss the second part of the 2024 CKD guidelines from KDIGO. Lots to chew on, so let’s dive in!
Background
This week, we will discuss the 2024 KDIGO Guidelines on CKD, part 1. In this section we will discuss the first two chapters on CKD evaluation and risk stratification. Let’s dive in!
